Olpruva
(Sodium phenylbutyrate)Phase 1
Olpruva is one of 18 small molecule programs targeting Diabetes. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
17
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Diabetes
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Mounjaro
Eli LillyApproved
Singulair
OOrganon and Co
Approved
Inulin and Sodium Chloride
BBlue Earth Diagnostics
Approved
Taltz
Eli LillyPhase 2
Berberine
XXijing Hospital of Digestive Diseases
Phase 3
Myalept
Chiesi Farmaceutici S.p.A.Phase 2
NOVOLIN R
Novo NordiskPreclinical
Sodium Benzoate
LLiminal BioSciences Ltd.
Phase 1
Formoterol Furmarate (20 Μg)
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Apr 30, 1996
BUPHENYL
NDA NDA020573
May 13, 1996
BUPHENYL
NDA NDA020572
Jun 17, 2022
PHEBURANE
NDA NDA216513
Oct 10, 2025
OLPRUVA
NDA NDA214860
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sodium phenylbutyrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- HHorizon Therapeutics Ireland DAC